Are you over 18 and want to see adult content?
More Annotations
A complete backup of ourworldindata.org
Are you over 18 and want to see adult content?
A complete backup of twinbeechforum.com
Are you over 18 and want to see adult content?
A complete backup of smith-haut-lafitte.com
Are you over 18 and want to see adult content?
A complete backup of maddonnasnashville.com
Are you over 18 and want to see adult content?
A complete backup of polymer-project.org
Are you over 18 and want to see adult content?
A complete backup of cruisecompete.com
Are you over 18 and want to see adult content?
Favourite Annotations
پت شاپ اینترنتی باران پت | ارسال رایگان غذا و لوازم حیوانات خانگی
Are you over 18 and want to see adult content?
Gjirafa50 - Dyqani online më i madh për teknologji në Kosovë dhe rajon.
Are you over 18 and want to see adult content?
AdLock - Download the Most Functional Ad Blocker to Remove Ads & Pop-ups
Are you over 18 and want to see adult content?
BioSkin | Performance, Preventative and Post-Injury Bracing
Are you over 18 and want to see adult content?
3D Rendering & Architectural Visualisation Service - The 3D Architect
Are you over 18 and want to see adult content?
УТРАЧЕННЫЕ ШЕДЕВРЫ — LiveJournal
Are you over 18 and want to see adult content?
Text
INVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase BRAINSTORM ANNOUNCES SCIENTIFIC PRESENTATION OF NUROWN NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn ®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, beingINVESTORS & MEDIA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 DAVID SETBOUN, PHD, MBA Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States. JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
BRAINSTORM – DISCOVER, INNOVATE, DELIVER – DELIVERING ONSCIENCEPIPELINEPATIENTS & CAREGIVERSINVESTORS & MEDIALEADERSHIPCAREERS Discover. Innovate. Deliver.BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE Phase 3 Pivotal Trial in ALS is Now Complete Read More Phase 2 Trial in Progressive MS is Now Fully Enrolled Read More OUR MISSION BrainStorm is dedicated to defeating neurodegenerative diseasesINVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase BRAINSTORM ANNOUNCES SCIENTIFIC PRESENTATION OF NUROWN NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn ®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, beingINVESTORS & MEDIA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 DAVID SETBOUN, PHD, MBA Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States. JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
PIPELINE - BRAINSTORM Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellularPUBLICATIONS
Publications View View View View View View View View View View View View View View View View View View View ViewINVESTORS & MEDIA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 LEADERSHIP - BRAINSTORM Leadership Executive Team Board of Directors Prof. Jacob Frenkel ?Irit Arbel, PhD Sankesh Abbhi June Almenoff, MD, PhD Anthony Polverino, PhD Malcolm Taub Uri Yablonka scientific advisory board Jerold Chun, MD, PhD Stanley H. Appel, MD Amit Bar-Or, MD BRAINSTORM ANNOUNCES FULL YEAR 2020 FINANCIAL RESULTS AND "In 2020 we achieved several important company milestones, the most significant of which was the timely completion of our pivotal Phase 3 ALS trial," said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics."The trial generated robust data suggesting that NurOwn® has a clinically meaningful treatment effect and the FDA is actively reviewing these data following a recentYAEL GOTHELF, PHD
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 RALPH KERN, MD, MHSC Ralph Kern, MD, MHSc, is the President and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization. BRAINSTORM ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy.The study, entitled "MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS BRAINSTORM ANNOUNCES SCIENTIFIC PRESENTATION OF NUROWN NEW YORK, Oct. 19, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF (NurOwn®) Exosomes: A Novel Therapeutic Modality in the Mouse LPS-induced ARDS model Analysis" at the NYSCF Conference Meeting, being held virtually. JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
BRAINSTORM – DISCOVER, INNOVATE, DELIVER – DELIVERING ONSCIENCEPIPELINEPATIENTS & CAREGIVERSINVESTORS & MEDIALEADERSHIPCAREERS Discover. Innovate. Deliver.BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE Phase 3 Pivotal Trial in ALS is Now Complete Read More Phase 2 Trial in Progressive MS is Now Fully Enrolled Read More OUR MISSION BrainStorm is dedicated to defeating neurodegenerative diseasesINVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). PIPELINE - BRAINSTORM Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular BRAINSTORM ANNOUNCES SCIENTIFIC PRESENTATION OF NUROWN NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn ®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, being BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase DAVID SETBOUN, PHD, MBA Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States. JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
BRAINSTORM – DISCOVER, INNOVATE, DELIVER – DELIVERING ONSCIENCEPIPELINEPATIENTS & CAREGIVERSINVESTORS & MEDIALEADERSHIPCAREERS Discover. Innovate. Deliver.BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE Phase 3 Pivotal Trial in ALS is Now Complete Read More Phase 2 Trial in Progressive MS is Now Fully Enrolled Read More OUR MISSION BrainStorm is dedicated to defeating neurodegenerative diseasesINVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). PIPELINE - BRAINSTORM Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular BRAINSTORM ANNOUNCES SCIENTIFIC PRESENTATION OF NUROWN NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn ®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, being BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase DAVID SETBOUN, PHD, MBA Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States. JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). BRAINSTORM ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS NEW YORK, April 26, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2021 and provided a corporate update. LEADERSHIP - BRAINSTORM Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460YAEL GOTHELF, PHD
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 BRAINSTORM ANNOUNCES FULL YEAR 2020 FINANCIAL RESULTS AND "In 2020 we achieved several important company milestones, the most significant of which was the timely completion of our pivotal Phase 3 ALS trial," said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics."The trial generated robust data suggesting that NurOwn® has a clinically meaningful treatment effect and the FDA is actively reviewing these data following a recentINVESTORS & MEDIA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460INVESTORS & MEDIA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 RALPH KERN, MD, MHSC Ralph Kern, MD, MHSc, is the President and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization.SANKESH ABBHI
Sankesh Abbhi is the President and CEO of ArisGlobal, a leading provider of cloud-based, end-to-end, drug development technology solutions for over 250 of the world’s leading Life Science’s companies, CROs and government health authorities. BRAINSTORM ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy.The study, entitled "MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS BRAINSTORM – DISCOVER, INNOVATE, DELIVER – DELIVERING ONSCIENCEPIPELINEPATIENTS & CAREGIVERSINVESTORS & MEDIALEADERSHIPCAREERS Discover. Innovate. Deliver.BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE Phase 3 Pivotal Trial in ALS is Now Complete Read More Phase 2 Trial in Progressive MS is Now Fully Enrolled Read More OUR MISSION BrainStorm is dedicated to defeating neurodegenerative diseasesINVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
PIPELINE - BRAINSTORM Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase LEADERSHIP - BRAINSTORM Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States.YAEL GOTHELF, PHD
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
BRAINSTORM – DISCOVER, INNOVATE, DELIVER – DELIVERING ONSCIENCEPIPELINEPATIENTS & CAREGIVERSINVESTORS & MEDIALEADERSHIPCAREERS Discover. Innovate. Deliver.BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE Phase 3 Pivotal Trial in ALS is Now Complete Read More Phase 2 Trial in Progressive MS is Now Fully Enrolled Read More OUR MISSION BrainStorm is dedicated to defeating neurodegenerative diseasesINVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
PIPELINE - BRAINSTORM Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase LEADERSHIP - BRAINSTORM Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States.YAEL GOTHELF, PHD
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
SCIENCE - BRAINSTORM Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Science Autologous Cellular Therapy Autologous cellular therapy has recently emerged as a credible and practical treatment option for cancer and other highly debilitating diseases. BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treatingPUBLICATIONS
Publications View View View View View View View View View View View View View View View View View View View View PATIENTS & CAREGIVERS About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources Patients & Caregivers About ALS Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a progressive disease that causes damage to cells in the brain and spinal cord known as motor neurons. Motor neurons transmit signals from the brainPRE-APPROVAL FORM
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 BRAINSTORM ANNOUNCES SCIENTIFIC PRESENTATION OF NUROWN NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn ®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, being DAVID SETBOUN, PHD, MBA Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460INVESTORS & MEDIA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 RALPH KERN, MD, MHSC Ralph Kern, MD, MHSc, is the President and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization. JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
ARTURO ARAYA, MBA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 BRAINSTORM – DISCOVER, INNOVATE, DELIVER – DELIVERING ONSCIENCEPIPELINEPATIENTS & CAREGIVERSINVESTORS & MEDIALEADERSHIPCAREERS Discover. Innovate. Deliver.BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE Phase 3 Pivotal Trial in ALS is Now Complete Read More Phase 2 Trial in Progressive MS is Now Fully Enrolled Read More OUR MISSION BrainStorm is dedicated to defeating neurodegenerative diseasesINVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
PIPELINE - BRAINSTORM Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase LEADERSHIP - BRAINSTORM Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States.YAEL GOTHELF, PHD
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
BRAINSTORM – DISCOVER, INNOVATE, DELIVER – DELIVERING ONSCIENCEPIPELINEPATIENTS & CAREGIVERSINVESTORS & MEDIALEADERSHIPCAREERS Discover. Innovate. Deliver.BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE Phase 3 Pivotal Trial in ALS is Now Complete Read More Phase 2 Trial in Progressive MS is Now Fully Enrolled Read More OUR MISSION BrainStorm is dedicated to defeating neurodegenerative diseasesINVESTORS & MEDIA
Company Information. BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), MultipleSclerosis (MS) and
PIPELINE - BRAINSTORM Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular BRAINSTORM ANNOUNCES TOPLINE RESULTS FROM NUROWN® PHASE 3 NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). BRAINSTORM ANNOUNCES POSITIVE TOPLINE DATA IN PHASE 2 NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). BRAINSTORM ANNOUNCES HIGH-LEVEL FDA FEEDBACK ON NUROWN NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase LEADERSHIP - BRAINSTORM Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460CHAIM LEBOVITS
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States.YAEL GOTHELF, PHD
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
SCIENCE - BRAINSTORM Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Science Autologous Cellular Therapy Autologous cellular therapy has recently emerged as a credible and practical treatment option for cancer and other highly debilitating diseases. BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treatingPUBLICATIONS
Publications View View View View View View View View View View View View View View View View View View View View PATIENTS & CAREGIVERS About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources Patients & Caregivers About ALS Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a progressive disease that causes damage to cells in the brain and spinal cord known as motor neurons. Motor neurons transmit signals from the brainPRE-APPROVAL FORM
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 BRAINSTORM ANNOUNCES SCIENTIFIC PRESENTATION OF NUROWN NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn ®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, being DAVID SETBOUN, PHD, MBA Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460INVESTORS & MEDIA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 RALPH KERN, MD, MHSC Ralph Kern, MD, MHSc, is the President and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization. JUNE ALMENOFF, MD, PHD Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for$1.2B.
ARTURO ARAYA, MBA
Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460Skip to content
Main Menu
* Science Menu Toggle * Autologous Cellular Therapy* MSC-NTF Cells
* MSC-NTF Cell Production* Publications
* Pipeline Menu Toggle* Pipeline
* Pipeline Overview
* Patients & CaregiversMenu Toggle
* About ALS
* About Progressive MS* Clinical Trials
* Preapproval Access Policies* Resources
* AboutMenu Toggle
* Leadership Menu Toggle* Executive Team
* Board of Directors * Scientific Advisory Board* Careers
* Investors & Media Menu Toggle* Overview
* News
* Events and Presentations* Stock Information
* Financial Reports & Filings * Corporate Governance* Contact
*
* vimeo
Discover. Innovate. Deliver. BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.LEARN MORE
* __
PHASE 3 PIVOTAL TRIAL IN ALS IS NOW COMPLETERead More
PHASE 2 TRIAL IN PROGRESSIVE MS IS NOW FULLY ENROLLEDRead More
OUR MISSION
BRAINSTORM IS DEDICATED TO DEFEATING NEURODEGENERATIVE DISEASES USING AN INNOVATIVE, BEST-IN-CLASS, AUTOLOGOUS CELLULAR THERAPEUTIC TECHNOLOGY PLATFORM, TERMED NUROWN®. NUROWN® TECHNOLOGY PLATFORM__ Play Video
BrainStorm’s autologous MSC-NTF cell therapy is investigational andnot FDA approved.
* __
Defining a new class of autologous cellular therapeutics GROUNDED IN BREAKTHROUGH SCIENTIFIC INNOVATION AND FOCUSED ON UNMET MEDICAL NEED, BRAINSTORM IS BUILDING A BEST-IN-CLASS PLATFORM, NUROWN®, FOR PRODUCTION OF COMMERCIAL-READY MSC-NTF CELLS TO TREAT HIGHLY DEBILITATING NEURODEGENERATIVE DISEASES THAT CURRENTLY HAVE LIMITED TREATMENT OPTIONS.Read more
WHAT WE DO
BRAINSTORM CELL THERAPEUTICS, INC. (NASDAQ: BCLI) IS A CLINICAL-STAGE, PUBLICLY-TRADED BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF BEST-IN-CLASS AUTOLOGOUS CELLULAR THERAPEUTICS FOR THE TREATMENT OF HIGHLY DEBILITATING NEURODEGENERATIVE DISEASES. BrainStorm’s autologous MSC-NTF cell therapy has received Fast Track designation from the U.S. Food and Drug Administration (U.S. FDA) in amyotrophic lateral sclerosis (ALS) and has additionally been granted Orphan Status by the U.S. FDA and the European Medicines Agency (EMA). BrainStorm has completed a phase 3 pivotal trial using repeat-administration of autologous MSC-NTF cells in ALS in the UnitedStates.
Read More
BrainStorm has fully enrolled a phase 2 study of autologous MSC-NTF cells in patients with progressive multiple sclerosis (MS). Learn more.
__
__
CONTACT
CORPORATE HEADQUARTERS 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460BRAINSTORM
* Science
* Pipeline
* Investors & Media
* Patients & Caregivers* Leadership
* Careers
* Contact
Facebook __
Linkedin __
Twitter __
Vimeo __
Copyright 2019, BrainStorm Cell Limited. All rights reserved.Website by Chauk .
* Privacy Policy
* Terms of Use
* Sitemap
Scroll to Top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0